12,937 Shares in Akero Therapeutics, Inc. (NASDAQ:AKRO) Purchased by Creative Planning

Creative Planning purchased a new position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,937 shares of the company’s stock, valued at approximately $371,000.

Several other hedge funds have also recently modified their holdings of the stock. Janus Henderson Group PLC raised its position in shares of Akero Therapeutics by 42.2% during the 1st quarter. Janus Henderson Group PLC now owns 6,121,970 shares of the company’s stock worth $154,589,000 after purchasing an additional 1,815,569 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Akero Therapeutics by 10.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,060,479 shares of the company’s stock worth $102,569,000 after purchasing an additional 384,555 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after purchasing an additional 584,875 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of Akero Therapeutics by 14.6% during the 1st quarter. Baker BROS. Advisors LP now owns 2,713,205 shares of the company’s stock worth $68,536,000 after purchasing an additional 344,827 shares during the last quarter. Finally, Redmile Group LLC raised its position in shares of Akero Therapeutics by 67.5% during the 1st quarter. Redmile Group LLC now owns 1,858,702 shares of the company’s stock worth $46,951,000 after purchasing an additional 749,226 shares during the last quarter.

Akero Therapeutics Trading Down 1.2 %

AKRO stock opened at $34.87 on Friday. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12 month low of $13.39 and a 12 month high of $37.00. The firm has a 50-day moving average of $28.72 and a two-hundred day moving average of $25.04.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.09. As a group, equities research analysts expect that Akero Therapeutics, Inc. will post -3.64 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Insider Activity

In other news, CFO William Richard White sold 75,159 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $27.21, for a total value of $2,045,076.39. Following the completion of the sale, the chief financial officer now owns 41,791 shares of the company’s stock, valued at $1,137,133.11. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Andrew Cheng sold 1,738 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $26.18, for a total value of $45,500.84. Following the completion of the sale, the chief executive officer now owns 605,417 shares of the company’s stock, valued at $15,849,817.06. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO William Richard White sold 75,159 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $27.21, for a total transaction of $2,045,076.39. Following the completion of the sale, the chief financial officer now directly owns 41,791 shares of the company’s stock, valued at approximately $1,137,133.11. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 428,397 shares of company stock valued at $12,997,971 in the last 90 days. Company insiders own 7.94% of the company’s stock.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.